30.88
price down icon0.19%   -0.06
after-market Dopo l'orario di chiusura: 30.58 -0.30 -0.97%
loading
Precedente Chiudi:
$30.94
Aprire:
$31.26
Volume 24 ore:
1.60M
Relative Volume:
0.71
Capitalizzazione di mercato:
$4.54B
Reddito:
$264.79M
Utile/perdita netta:
$-14.36M
Rapporto P/E:
-280.73
EPS:
-0.11
Flusso di cassa netto:
$-28.11M
1 W Prestazione:
+0.55%
1M Prestazione:
+3.42%
6M Prestazione:
+23.18%
1 anno Prestazione:
+137.17%
Intervallo 1D:
Value
$30.37
$31.50
Intervallo di 1 settimana:
Value
$29.73
$31.57
Portata 52W:
Value
$12.90
$36.84

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name
Nome
Tg Therapeutics Inc
Name
Telefono
(212) 554-4484
Name
Indirizzo
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Name
Dipendente
0
Name
Cinguettio
@TGTherapeutics
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
TGTX's Discussions on Twitter

Confronta TGTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TGTX
Tg Therapeutics Inc
30.88 4.54B 264.79M -14.36M -28.11M -0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-10-29 Iniziato TD Cowen Buy
2023-08-02 Aggiornamento Goldman Sell → Neutral
2023-06-26 Ripresa Jefferies Buy
2022-05-20 Iniziato BofA Securities Underperform
2022-02-23 Reiterato B. Riley Securities Buy
2021-11-15 Downgrade Goldman Neutral → Sell
2021-04-20 Iniziato Goldman Neutral
2021-04-19 Reiterato H.C. Wainwright Buy
2020-09-01 Iniziato JP Morgan Overweight
2020-08-11 Reiterato H.C. Wainwright Buy
2020-06-05 Iniziato Evercore ISI Outperform
2020-01-17 Reiterato H.C. Wainwright Buy
2019-11-27 Ripresa B. Riley FBR Buy
2019-02-06 Ripresa Jefferies Buy
2018-09-25 Downgrade Raymond James Strong Buy → Outperform
2018-03-09 Reiterato B. Riley FBR, Inc. Buy
2017-12-01 Ripresa B. Riley FBR, Inc. Buy
2017-11-14 Ripresa H.C. Wainwright Buy
2017-04-25 Iniziato Jefferies Buy
2017-03-06 Reiterato FBR & Co. Outperform
2016-10-06 Ripresa Brean Capital Buy
2016-05-27 Iniziato SunTrust Buy
2015-12-01 Iniziato FBR Capital Outperform
2015-09-09 Iniziato Raymond James Strong Buy
2015-08-12 Ripresa H.C. Wainwright Buy
2015-06-19 Reiterato Brean Capital Buy
2014-12-11 Reiterato ROTH Capital Buy
2014-12-10 Reiterato ROTH Capital Buy
Mostra tutto

Tg Therapeutics Inc Borsa (TGTX) Ultime notizie

pulisher
Feb 18, 2025

TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Groundbreaking BRIUMVI MS Treatment Data: 4 Critical Studies Reveal Real-World Impact at ACTRIMS - StockTitan

Feb 18, 2025
pulisher
Feb 14, 2025

TG Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 14, 2025
pulisher
Feb 14, 2025

TG Therapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 16, 2022 to Discuss Your RightsTGTX - Newsfile

Feb 14, 2025
pulisher
Feb 14, 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Entropy Technologies LP - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Bleakley Financial Group LLC Purchases Shares of 8,140 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News

Feb 12, 2025
pulisher
Feb 12, 2025

46,655 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Strategic Financial Concepts LLC - MarketBeat

Feb 12, 2025
pulisher
Feb 12, 2025

How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months - Yahoo

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte signs SPL deal with TG Therapeutics - ShareCast

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell ... - The Bakersfield Californian

Feb 12, 2025
pulisher
Feb 10, 2025

SG Americas Securities LLC Has $233,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Stratos Wealth Advisors LLC Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 10, 2025
pulisher
Feb 08, 2025

Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St

Feb 08, 2025
pulisher
Feb 08, 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 08, 2025
pulisher
Feb 06, 2025

TGTX March 28th Options Begin Trading - Nasdaq

Feb 06, 2025
pulisher
Feb 06, 2025

Symphony Financial Ltd. Co. Acquires New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

Precision Wealth Strategies LLC Makes New $530,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Sell" at StockNews.com - MarketBeat

Feb 04, 2025
pulisher
Jan 30, 2025

Nisa Investment Advisors LLC Buys 2,803 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 30, 2025
pulisher
Jan 28, 2025

Trading (TGTX) With Integrated Risk Controls - Stock Traders Daily

Jan 28, 2025
pulisher
Jan 28, 2025

All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy - MSN

Jan 28, 2025
pulisher
Jan 25, 2025

TG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8%Here's What Happened - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Why TGTX Stock Is Rallying Today - MSN

Jan 25, 2025
pulisher
Jan 23, 2025

TG Therapeutics: Entering 2025 With Increased Investor Expectations (NASDAQ:TGTX) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Weighs in on TG Therapeutics FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Decreases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Jan 22, 2025
pulisher
Jan 21, 2025

TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha

Jan 21, 2025
pulisher
Jan 20, 2025

12 Hot Stocks to Buy According to Analysts - Insider Monkey

Jan 20, 2025
pulisher
Jan 20, 2025

Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey

Jan 20, 2025
pulisher
Jan 18, 2025

TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

(TGTX) Trading Signals - Stock Traders Daily

Jan 18, 2025
pulisher
Jan 18, 2025

Brookstone Capital Management Acquires 624 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

FY2024 EPS Forecast for TG Therapeutics Increased by Analyst - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

TG Therapeutics Provides Preliminary Fourth Quarter and Full-Year Financial Results in SEC Filing - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha

Jan 16, 2025
pulisher
Jan 16, 2025

TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN

Jan 15, 2025

Tg Therapeutics Inc Azioni (TGTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Tg Therapeutics Inc Azioni (TGTX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Power Sean A
CFO
Jan 06 '25
Sale
28.53
10,021
285,939
660,611
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
Capitalizzazione:     |  Volume (24 ore):